ASSESS is pleased to offer a brand-new training course which introduces life and health science innovators to the role of Early Health Technology Assessment (HTA) in their commercialisation journey.
There are revolutions in health care everywhere you look; from Artificial Intelligence, to gene therapies and robotics, tomorrow’s world is today. However, many of these innovations do not reach patients because health care systems are unable or unwilling to pay what innovators demand. When patients do get access, it is often months or years after the technology is licensed, undermining the commercial viability of the companies that develop them.
In addition to meeting the evidentiary demands of regulators like the MHRA, EMA and FDA, innovators must convince health technology assessment agencies like NICE, HAS, and iQWIG that their product good value for money to achieve market access. Equally, investment is harder to come by, and start-ups have to show investors the clear line of site between their activities and the likelihood of commercial success.
Early Health Technology Assessment helps innovators understand the new world of life sciences commercialisation, and design their research and development programme for success.
In this comprehensive one-day course, through a mixture of traditional lectures, practical exercises and group discussions, participants in the ASSESS EHTA course will leave with the knowledge and tools required to address the question ‘How do I demonstrate to health care funders that the value of my innovation justifies a commercially attractive price?’
